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ALD is clearly the rage. An advanced 
process for depositing ultra-thin films one
atomic layer at a time, for a range of chip
and compound semiconductor applica-
tions, the market for these deposition
tools is estimated at over $100m, growing
at 65% to reach $1.35bn by 2008, 
according to VLSI Research. 
Back last November, III-Vs Review record-
ed that one of the cannier players, Tegal,
had acquired Simplus Systems, a privately
held company with nano layer deposition
and MOCVD systems. The Simplus patent
NLD and plasma enhanced NLD are similar
to ALD, but are claimed to have a higher
throughput.
Since then it has certainly become the
fashionable acquisition technology for
machine vendors. 
Witness in April, Novellus Systems Inc
embraced Angstron Systems Inc - acquir-
ing them an ALD tool for 300mm copper
interconnect. 
ASM International N.V. went global shop-
ping and emerged with the South Korean
supplier Genitech Inc and its plasma-
enhanced ALD equipment. 
In June, not to be outdone, Aixtron under-
took to team up with ALD supplier Genus
for the supply of an atomic vapour deposi-
tion system. The combined cluster
machine with the understandable nomen-
clature, TriLynx, incorporates not only AVD,
ALD, but also RTP. 
And if anyone doubted the market stand-
ing of ALD, it was hallmarked in June,
when the mighty AMAT acquired Torrex
Inc, with its 200 and 300mm mini-batch
(50 wafers at a go) Flexstar systems, that
handle low pressure CVD. Its target niche
is claimed to be in hybrid silicon nitride
and silicon dioxide films.
One that’s stayed clear of larger partners
is Aviza Technology, which supplies ALD
and vertical furnaces. At Semicon it
launched the Verano 5000 - a mini batch,
200 and 300mm ALD system, designed to
deposit niche high k films (Al2O3, HfO2 and
HfSiOx). 
President and CEO, Jerry Cutini is  prag-
matically on record that he thinks the ALD
market is“over-hyped.”
Certainly while the machine markets may
look attractive, much less quantifiable but
probably much more interesting is the
value of those machines’ output, which
appear to range from high-k gate stacks,
DRAM and capacitors, through to nano
and MEMS. 
But of the Semicon machine showing, one
that raises a challenge is nFusion, gas
cluster ion beam epitaxy.  Originating two
decades ago in Kyoto and one-time owned
by JDSU, it is now with Epion Corp, offers
‘infusion’ and does seem to work the
magic with germanium. What remains to
be seen is has it the same skills for silicon
carbide?
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